A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus

NCT04682873 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

592

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid-19 Disease

Interventions

DRUG: Enisamium Iodide
DRUG: Placebo

Sponsor

Joint Stock Company "Farmak"